Collegium Reports Record Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies
November 11, 2024 3:55 PM ESTJefferies analyst Glen Santangelo lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $40.00 (from $44.00) while maintaining a Buy rating.
The analyst comments "Model update post 3Q results. Overall, we remain encouraged by momentum in the underlying pain portfolio, coupled with new LT... More
